EudraCT 2018-000978-30
31 evidence topics · 1 source
Objective
Safety of simultaneous administration and effects on cognition
“The aim of this study was to explore the safety of simultaneous administration of psilocybin to healthy participants in the largest randomised controlled trial of psilocybin to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study aimed to evaluate the safety and feasibility of simultaneous administration of single doses of either 10 or 25 mg doses of psilocybin compared with placebo in healthy participants, administered in a supervised setting with one-to-one psychological support, and to assess the short- and long-term effects of psilocybin on key domains of cognitive functioning.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is important to study the safety and feasibility of this model of simultaneous administration as it could be a more effective, time- and cost-efficient model of treatment delivery, meaning more patients could potentially benefit from this treatment, if approved.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Single site in London, August 2018 to July 2019
“The first participant’s first visit date was August 17, 2018, and the last participant’s last visit date was July 19, 2019.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the NIHR/Wellcome Trust Clinical Research Facility at King’s College Hospital, where this study was undertaken.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Phase 1, randomized, double-blind, placebo-controlled design
“This was a phase 1, randomised, double-blind, placebo-controlled, between-groups study to evaluate the effects of single 10 and 25 mg doses of psilocybin compared with placebo in healthy participants, conducted at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK, sponsored by COMPASS Pathways (EudraCT number: 2018-000978-30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were followed up for 12 weeks after study drug administration” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was funded and sponsored by COMPASS Pathways, London, UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Stratified randomization with individual allocation within shared sessions
“Participants were stratified by sex and age (18–35 years old; >35 years old) and randomised in a 1:1:1 ratio using blocked randomisation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were randomised on an individual basis and therefore participants in the same dosing session could be allocated to different treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Healthy adults without recent psilocybin use
“The study recruited healthy participants (male or female; aged 18−65 years at screening) with no psilocybin experience within 1 year prior to enrolment; the study aimed to recruit up to 90 participants who met eligibility criteria at the screening visit (visit 1; day -56 to day -2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were recruited via online advertisements and word of mouth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Inclusion criteria, psychiatric exclusion criteria (including current/history of psychiatric disorders, current/recent psychiatric medications, or other psilocybin-incompatible psychiatric or psychological conditions, as judged by the investigator), and medical exclusion criteria are listed in the Supplementary Methods.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single oral dose of COMP360 10 mg or 25 mg, or placebo, as five capsules
“The study drug was administered simultaneously to up to six participants as a single 5-capsule oral dose (psilocybin 10 mg: 2 × 5 mg psilocybin capsules plus 3 × placebo capsules; psilocybin 25 mg: 5 × 5 mg psilocybin capsules; placebo: 5 × placebo capsules).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“COMP360 psilocybin was administered in this study, which is COMPASS Pathways’ proprietary pharmaceutical-grade synthetic psilocybin formulation that has been optimised for stability and purity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Group preparation, simultaneous administration session, and integration
“During this visit, participants attended a 2-h group preparatory session (involving all participants to be dosed the following day, a lead therapist and assisting therapists) and had a short (5–15 min) individual discussion with their assigned assisting therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Administration sessions generally lasted ~6–8 h, with psychological support available throughout from specially trained assisting therapists, who were supervised by a lead therapist.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The simultaneous dosing involved each participant having a private space, for example, a bed separated by curtains within the same room, so they could focus on their own experience with minimal distractions, especially as participants were encouraged to wear eyeshades, earplugs and/or earphones for the duration of the administration session.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were subsequently discharged and asked to return the following day (day 1; visit 4) for safety assessments and a discussion with their allocated therapist about the subjective experience during the administration session (integration session).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using CANTAB cognitive measures as the primary endpoint
Rationale for studying cognitive and emotional processing
“Psilocybin’s effects on cognitive function have not been widely or systematically studied.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neural correlates of cognitive and emotional processing are considered important therapeutic targets in the development of novel treatments for treatment-resistant depression and other mental disorders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given this unmet need for improved treatment of social and emotional functioning deficits, a better understanding of the short- and long-term effects of psilocybin on emotional processing and social cognition is required.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, it has not yet been investigated whether the beneficial effects of psilocybin may also benefit general cognitive abilities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given the potential for psilocybin as a treatment for a range of conditions, studying its effects on cognition is important.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary efficacy endpoints: CANTAB measures and social cognition scales
“The primary efficacy endpoints were short-term change from baseline (day -1) to day 8 in cognitive measures of attention, spatial and working memory and executive function” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“short-term change from baseline to day 8 in social cognition, emotional processing scales (comprising the Pictorial Empathy Test (PET); Reading the Mind in the Eyes Test (RMET); Scale of Social Responsibility (SSR); Social Value Orientation (SVO); and Toronto Empathy Questionnaire (TEQ)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“change from baseline to day 29 in the individual cognitive functioning assessments previously outlined; and long-term change from baseline to day 85 in social cognition, emotional processing scales.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CANTAB global composite score as a safety endpoint
“Safety was assessed via endpoints which included cognitive function, assessed by CANTAB global composite score, and treatment-emergent adverse event (TEAE) monitoring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cognitive function was measured by the Cambridge Neuropsychological Test Automated Battery (CANTAB) global composite score change from baseline (day -1) to day 8 and 29, calculated from Z scores for each CANTAB measure (Paired Associates Learning-Total Errors Adjusted (PAL-TEA; a measure of episodic memory); Spatial Working Memory-Between Errors (SWM-BE; working memory); SWM-Strategy (SWM-S; executive function and planning); and Rapid Visual Information Processing A-prime (RVP-A’; sustained attention); a higher CANTAB global composite score indicates better cognitive function).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Familiarization session to limit practice effects
“At screening, participants underwent CANTAB assessments as part of a familiarisation session; this was included in the descriptive statistics but was excluded from statistical modelling.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The purpose of familiarisation was to ensure that all the participants had a chance to practice the tests prior to the collection of the baseline data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary efficacy endpoints
“Secondary efficacy endpoints included dose-related differences in the cognitive effects of psilocybin at baseline, day 8 and day 29, measured by the CANTAB assessments RVP-Aʹ, SWM-BE, SWM-S, PAL-TEA; dose-related differences in the psychological effects of psilocybin at baseline, day 8 and day 85, measured by the social cognition, emotional processing scales; differences in the cognitive effects of psilocybin between psilocybin-naïve and -experienced participants at baseline, day 8 and day 29, measured by the CANTAB global composite score; and differences in PANAS after study drug administration on day 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample of up to 90 participants
“A sample size of up to 90 participants (30 per treatment group) was chosen to allow reasonable assessment of each of the planned endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study was exploratory and therefore not adequately powered to detect statistical significance; as such p values are not reported.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 30 participants were randomised to receive 25 mg psilocybin, 30–10 mg psilocybin and 29 to placebo; 33 (37.1%) participants had prior psilocybin experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Safety, modified intent-to-treat, and per-protocol populations
“The Safety Population comprised all randomised participants who received study drug and was used for all summaries of participant accountability, demographic and baseline data, and safety information, including AE incidence and cognition endpoint analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The modified Intent-to-Treat (mITT) Population comprised all participants in the Safety Population who had at least one post-dose assessment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This population was used for emotional processing endpoint analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Per-Protocol (PP) Population comprised all participants in the Safety Population who did not have a major protocol deviation that was thought to significantly affect the integrity of the participant’s data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This population was used for the CANTAB primary endpoint analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mixed model for repeated measures
“The MMRM method utilises the observed data efficiently, handling missing data automatically, based on the assumption that data are missing at random, thus minimising bias in the estimates of treatment effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Randomized, dosed, and completed
“The study randomised 89 healthy participants (mean age, 36.1 years; 41 females, 48 males)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants randomised to both psilocybin arms completed the study; four (13.8%) placebo-treated participants did not complete all study visits (three were lost to follow-up; one was withdrawn following a protocol deviation).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-five administration sessions were completed, with up to six participants dosed simultaneously per session (there were 2 sessions with one participant each, 3 with two, 5 with three, 11 with four, 2 with five and 2 with six).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Participant demographics, safety population
Efficacy results
CANTAB measures: least squares mean difference from placebo
“For PAL-TEA, SWM-BE and SWM-S, lower scores denote better performance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For RVP-A’ and CANTAB composite, higher scores denote better performance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no clinically relevant between-group differences in CANTAB global composite score, CANTAB cognitive domain scores, or emotional processing scale scores.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the CANTAB composite score, performance was worse than placebo for the 10 mg psilocybin group at day 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, this result is due in part to the larger improvement in performance from baseline by the placebo group at day 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the 10 mg psilocybin group, performance increased again by day 29 to a level similar to placebo suggesting no adverse effects of the 10 mg psilocybin dose compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Social cognition and emotional processing scales: least squares mean difference from placebo
“There was no difference between either psilocybin group and placebo in any social cognition and emotional processing scale (PET, RMET, SSR, SVO, or TEQ) scores at day 8 or day 85, relative to baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings suggest that psilocybin does not exert any detrimental effect on the social cognition and emotional functions assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Positive and negative affect after dosing
“The placebo group showed a trend for a reduction in positive affect score from baseline to post-dose (least squares (LS) mean change = -5.0), which was not observed in either psilocybin group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, the 25 mg psilocybin group showed a trend for an increase in LS mean negative affect score from baseline of 1.3, compared with no change in the 10 mg psilocybin and placebo groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Most frequent treatment-emergent adverse events and events of special interest, safety population
Overall incidence, relatedness, and duration
“In total, 511 TEAEs were reported during the 12-week study: 217 in the 25 mg psilocybin arm (reported by 29 (96.7%) participants), 203 in the 10 mg psilocybin arm (reported by 29 (96.7%) participants) and 91 in the placebo arm (reported by 26 (89.7%) participants).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of these, 208, 188 and 77 were deemed by the investigator to be potentially related to study treatment in the 25 mg, 10 mg and placebo arms, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no serious TEAEs and no AEs led to withdrawal from the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Across all AEs reported in all treatment arms throughout the 12 week study, 67% started and resolved on the administration day; the median duration of AEs was 1.0 day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and substance-induced psychotic disorder on the day of dosing
“Four participants reported AEs of anxiety on the day of study drug administration (25 mg psilocybin, n = 2 (6.7%); 10 mg psilocybin, n = 1 (3.3%); placebo, n = 1 (3.4%))” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An AE of substance induced psychotic disorder was reported for a participant who became behaviourally disinhibited during the acute drug experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a medical assessment, 2.5 mg oromucosal midazolam was administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The participant recovered with no sequelae and was discharged 11 h after receiving the study intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Suicidality on the Sheehan Suicidality Tracking Scale
“At baseline, all participants recorded an SSTS score of 0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During follow-up, no participants in the 25 mg psilocybin arm recorded an SSTS score > 0; however, one participant in the 10 mg psilocybin arm recorded a highest score of 1 during follow-up (reported at the day 29 visit).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This participant reported a TEAE of suicidal thoughts (one event), which started and resolved on day 19, was mild in severity and was deemed by the investigator to be possibly related to study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laboratory tests and vital signs
“There were four clinically significant clinical laboratory assessment findings, which were recorded as AEs (none of which prevented the participant from entering or continuing in the study).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no clinically significant findings in vital signs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: healthy participants, exploratory sample size, blinding not assessed, practice effects, sponsor involvement
The study enrolled 89 healthy participants who were typically highly educated, and 37% of the sample had previous psilocybin experience; the authors state that these factors and the small sample size could have limited generalisability and that the findings warrant investigation in clinical populations. The sample size was not powered to detect statistically significant differences, and p values were not reported. Blinding efficacy was not assessed, and the authors state that participants may have been able to determine their assigned treatment group. Practice effects could have influenced results, and outcomes were measured at day 8 and at day 29 or 85. The study was funded and sponsored by COMPASS Pathways, and several authors are employees or former employees of the company.
Exploratory design without power for efficacy comparisons
“however, our sample size was not powered to detect statistically significant differences in psilocybin efficacy between groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Instead, this was an exploratory evaluation of the efficacy and safety of psilocybin compared with placebo; caution should therefore be taken when interpreting these results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Healthy, highly educated, psilocybin-experienced sample
“The fact that participants were typically highly educated, and the small sample size, could have limited the generalisability of results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings warrant further investigation in clinical populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With thirty-five participants reporting previous use of psilocybin in this study, the proportion of participants with prior experience is greater than expected in the general population, thus additional caution should be taken when generalising these results to other populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blinding not assessed
“The efficacy of the blinding was not assessed in this study and therefore we cannot rule out the potential that guessing the treatment assignment influenced results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given psilocybin’s psychedelic effects, combined with the fact that 37% of the total sample had previous experience using psilocybin, it is possible that these participants may have been able to determine their assigned treatment group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Practice effects and assessment timepoints
“It is possible that practice effects could have influenced results.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The current study measured the short-term effects of psilocybin at day 8, and longer-term effects at day 29 or 85.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future research would benefit from collecting outcomes at later time points post-dosing to gain a broader understanding of more long-term effects, and also acutely, either immediately after or during psilocybin administration.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor involvement
“ML-J, LM, SM, FS, SS, SW, HE and EM are employees or former employees of COMPASS Pathways plc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This assistance was funded by COMPASS Pathways plc, London, UK.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote